Pfizer jab lowers infection risk by 93% in teens, Israelis find

News

Pfizer jab lowers infection risk by 93% in teens, Israelis find

Three-month study confirms Pfizer’s effectiveness against the deadly Delta variant

Cape Town bureau chief

The launch of vaccinations for 12- to 17-year-olds on Wednesday coincided with new findings that the Pfizer/BioNTech vaccine significantly decreases symptomatic Covid-19 in adolescents.

The three-month study in Israel, an early leader in Covid-19 vaccinations, involved almost 189,000 adolescents, equally split between vaccinated and unvaccinated.

The study, between July and September, coincided with Israel’s fourth wave of Covid-19 infections, during which the Delta variant was the dominant strain — as it is in SA...

This article is free to read if you register or sign in.

Sunday Times Daily

If you have already registered or subscribed, please sign in to continue.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.

Next Article

Previous Article